AviadoBio

AviadoBio is developing gene therapies for neurodegenerative diseases including frontotemporal dementia and amyotrophic lateral sclerosis. 

Graphic of two hands shaking under a red and purple light
Biotech

Astellas pays $50M for option on AviadoBio dementia gene therapy

Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity and upfront cash.
James Waldron Oct 8, 2024 7:40am
Fierce Biotech Fierce 15 logo

Fierce Biotech's 2022 Fierce 15

Sep 12, 2022 3:00am
CL chutes

2 Astellas execs to retire—Chutes & Ladders

Aug 5, 2022 9:46am
Gene therapy

AviadoBio gains orphan tag for one-dose dementia gene therapy

Apr 27, 2022 9:18am